FR2456522A1 - Insulin compsns. for admin via mucosa - contg. selected acids to increase absorption pref. also contg. a surfactant and a protease inhibitor - Google Patents

Insulin compsns. for admin via mucosa - contg. selected acids to increase absorption pref. also contg. a surfactant and a protease inhibitor

Info

Publication number
FR2456522A1
FR2456522A1 FR8010946A FR8010946A FR2456522A1 FR 2456522 A1 FR2456522 A1 FR 2456522A1 FR 8010946 A FR8010946 A FR 8010946A FR 8010946 A FR8010946 A FR 8010946A FR 2456522 A1 FR2456522 A1 FR 2456522A1
Authority
FR
France
Prior art keywords
acids
acid
insulin
pref
contg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR8010946A
Other languages
French (fr)
Inventor
Kenji Hara
Kyozaburo Tachibana
Seiji Naito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Kao Soap Co Ltd
Original Assignee
Kao Corp
Kao Soap Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP6129279A priority Critical patent/JPS5643443B2/ja
Application filed by Kao Corp, Kao Soap Co Ltd filed Critical Kao Corp
Publication of FR2456522A1 publication Critical patent/FR2456522A1/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules

Abstract

Insulin prepns. comprise insulin, a carrier for absorption via mucous membranes, and 0.01-0.5 wt.% of >=1 selected from (a) 1-6C alkanoic acid, (b) lower hydroxy carboxylic acid, (c) inorganic acids selected from HCl, H3PO4, HN3, phosphotungstic acid and HClO4, (d) benzoic, phthalic and pyromellitic acids, (e) monochloro-, dichloro-, trichloro- and sulpho-acetic acids, (f) acrylic and maleic acids, and (g) pyruvic, furoic and picric acids. The carrier is pref. a suppository base. Pref. acids are 1-5C alkanoic acids (esp. acetic), tartaric acid, glycolic acid, HCl, HNO3 and monochloroacetic acid. The prepns. can also contain a surfactant and a protease inhibitor. They are pref. produced by dissolving insulin in an aq. soln. of the acid and incorporating the soln. into the carrier (esp. molten suppository base). The prepns. are esp. useful for rectal, intravaginal or sublingual admin. giving large reductions in blood sugar levels at low insulin concns.
FR8010946A 1979-05-18 1980-05-14 Insulin compsns. for admin via mucosa - contg. selected acids to increase absorption pref. also contg. a surfactant and a protease inhibitor Withdrawn FR2456522A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP6129279A JPS5643443B2 (en) 1979-05-18 1979-05-18

Publications (1)

Publication Number Publication Date
FR2456522A1 true FR2456522A1 (en) 1980-12-12

Family

ID=13166964

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8010946A Withdrawn FR2456522A1 (en) 1979-05-18 1980-05-14 Insulin compsns. for admin via mucosa - contg. selected acids to increase absorption pref. also contg. a surfactant and a protease inhibitor

Country Status (3)

Country Link
JP (1) JPS5643443B2 (en)
DE (1) DE3018843A1 (en)
FR (1) FR2456522A1 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587621A1 (en) * 1985-09-09 1987-03-27 Berlin Chemie Veb Method for manufacturing pharmaceutical preparations of peptides presenting an increased resorption ability
EP0273202A2 (en) * 1986-12-23 1988-07-06 Eugene J. Dr. Van Scott Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots.
EP0302772A1 (en) * 1987-08-03 1989-02-08 Asahi Kasei Kogyo Kabushiki Kaisha Calcitonin composition for nasal administration
EP0332222A2 (en) * 1988-03-11 1989-09-13 Teikoku Seiyaku Co., Ltd. Intravaginal delivery of biologically active polypeptides
WO2003105888A1 (en) 2002-06-18 2003-12-24 Aventis Pharma Deutschland Gmbh Acidic insulin preparations with improved stability
US20070292355A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US7696162B2 (en) 2001-03-23 2010-04-13 Sanofi-Aventis Deutschland Gmbh Zinc-free and low-zinc insulin preparations having improved stability
US8013017B2 (en) 2001-05-31 2011-09-06 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10265404B2 (en) 2013-11-13 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56138110A (en) * 1980-03-28 1981-10-28 Teijin Ltd Suppository containing citric acid or salt thereof
JPH0242809B2 (en) * 1980-03-31 1990-09-26
JPS631923B2 (en) * 1980-03-31 1988-01-14 Teijin Ltd
JPS5780315A (en) * 1980-11-09 1982-05-19 Kyoto Yakuhin Kogyo Kk Absorption promotor for accelerating rectum absorption, base comprising it, and pharmaceutical preparation to be medicated to rectum
JPS6321704Y2 (en) * 1981-06-02 1988-06-15
SU1011126A1 (en) * 1981-07-14 1983-04-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Method of treating diabetes mellitus
JPH0136442B2 (en) * 1981-08-31 1989-07-31 Taiho Pharmaceutical Co Ltd
JPH0623092B2 (en) * 1984-03-19 1994-03-30 太陽化学株式会社 Suppository pharmaceutical composition
JPS61138863A (en) * 1984-12-11 1986-06-26 Honda Motor Co Ltd Engine body of internal-conbustion engine
JPH048302Y2 (en) * 1985-10-22 1992-03-03
JPH0521895B2 (en) * 1986-01-06 1993-03-25 Showa Pharm Chem Ind
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
US7635675B2 (en) 2003-08-13 2009-12-22 Biocon Limited Micro-particle fatty acid salt solid dosage formulations for therapeutic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL45481C (en) *
JPS5315412A (en) * 1976-07-27 1978-02-13 Ono Pharmaceut Co Ltd Suppository for diabetics
FR2455897A1 (en) * 1979-05-10 1980-12-05 Kyoto Pharma Ind Adjuvant fatty acid to promote the absorption of pharmacologically active substances by the rectum, base composition for rectal administration comprising this adjuvant and pharmaceutical composition comprising this adjuvant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL45481C (en) *
JPS5315412A (en) * 1976-07-27 1978-02-13 Ono Pharmaceut Co Ltd Suppository for diabetics
FR2455897A1 (en) * 1979-05-10 1980-12-05 Kyoto Pharma Ind Adjuvant fatty acid to promote the absorption of pharmacologically active substances by the rectum, base composition for rectal administration comprising this adjuvant and pharmaceutical composition comprising this adjuvant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA1978 *

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587621A1 (en) * 1985-09-09 1987-03-27 Berlin Chemie Veb Method for manufacturing pharmaceutical preparations of peptides presenting an increased resorption ability
EP0273202A2 (en) * 1986-12-23 1988-07-06 Eugene J. Dr. Van Scott Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots.
EP0273202A3 (en) * 1986-12-23 1990-06-06 Eugene J. Dr. Van Scott Additives enhancing topical actions of therapeutic agents
EP0302772A1 (en) * 1987-08-03 1989-02-08 Asahi Kasei Kogyo Kabushiki Kaisha Calcitonin composition for nasal administration
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
EP0332222A2 (en) * 1988-03-11 1989-09-13 Teikoku Seiyaku Co., Ltd. Intravaginal delivery of biologically active polypeptides
EP0332222A3 (en) * 1988-03-11 1991-03-06 Teikoku Seiyaku Co., Ltd. Intravaginal delivery of biologically active polypeptides
US5824646A (en) * 1988-03-11 1998-10-20 Teikoku Seiyaku Co., Ltd. Intravaginal delivery of biologically active polypeptides
US7696162B2 (en) 2001-03-23 2010-04-13 Sanofi-Aventis Deutschland Gmbh Zinc-free and low-zinc insulin preparations having improved stability
US9456970B2 (en) 2001-05-31 2016-10-04 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods
US8013017B2 (en) 2001-05-31 2011-09-06 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods
WO2003105888A1 (en) 2002-06-18 2003-12-24 Aventis Pharma Deutschland Gmbh Acidic insulin preparations with improved stability
US7713930B2 (en) 2002-06-18 2010-05-11 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
US7476652B2 (en) 2002-06-18 2009-01-13 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
HRP20041200B1 (en) * 2002-06-18 2013-05-31 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations with improved stability
EP2305288A3 (en) * 2002-06-18 2013-12-11 Sanofi-Aventis Deutschland GmbH Acidic insulin preparations with improved stability
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US20070292355A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10028910B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US10265404B2 (en) 2013-11-13 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients

Also Published As

Publication number Publication date
JPS55153712A (en) 1980-11-29
DE3018843A1 (en) 1980-11-20
JPS5643443B2 (en) 1981-10-13

Similar Documents

Publication Publication Date Title
AU558378B2 (en) Production of acetic acid, propionic acid and their esters
GR3026000T3 (en) Process for the preparation of esters of carboxylic acids from carboxylic acid halogenides and alcohols.
ES8500965A1 (en) Procedure for obtaining copolymers based on carboxylic acids
SE8206580D0 (en) The Tell-up of 3-hydroxy ML-236B derivatives
GB1384372A (en) Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
AU1673076A (en) Purification of acetic acid
FR2439178A1 (en) A process for preparing terephthalic acid
SE7809241A (en) Process for the production tell up of esters of penicillins, cephalosporins
JPH021473A (en) Imide aromatic peroxy acid as bleaching agent
GB8803422D0 (en) Dimerised fatty acids having high content of dicarboxylic acid
JPH01203373A (en) Derivative of thiazolidine-4-carboxylic acid having pharmacological activity
Schwenk et al. α-Bromination of Dicarboxylic Acids1
CA2076674A1 (en) Process for the accelerated production of stable solutions, in equilibrium, of peracetic acid in low concentrations
JPS5212126A (en) Process for preparation of methacrylic acid
IT7926487D0 (en) Interpolimeri hydrophilic obtained by photopolymerization of unsaturated carboxylic acid and esters of unsaturated carboxylic acids.
JPS51115414A (en) Process for preparation of unsaturated fatty acids
CA2112079A1 (en) Method of Preparing Intermediate DS Starch Esters in Aqueous Solution
JPH04230295A (en) New 17beta-hydroxybenzoyl-4-aza-5alpha-androst-1-ene-3-ones being testosterone reductase inhibitor
JPH01104095A (en) Preparation of methylene derivative of androsta-1,4-diene-3,17-dione
YU322675A (en) Process for the continuous separation of acetic acid from aqueous solutions of low concentrations
ZA8105881B (en) Surfactants which are polyhydric alcohol partial esters of adducts of maleic anhydride with an unsaturated carboxylic acid
JPH01262791A (en) Luciferase
GB1042631A (en) New fused polycyclic hydrocarbon derivatives and processes for the preparation thereof
GB1476981A (en) Substituted penicillanic acids
JPS5896100A (en) 12-oxocholanic acid tosylhydrazone compound, its preparation and use

Legal Events

Date Code Title Description
ST Notification of lapse